 Home > Active Ingredient News > Blood System > Blood: Effects of FLT3 inhibitor Gilteritinib vs salvage chemotherapy on long-term outcomes in patients with relapsed/refractory AML

Blood: Effects of FLT3 inhibitor Gilteritinib vs salvage chemotherapy on long-term outcomes in patients with relapsed/refractory AML

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

chemotherapy drugs classification

blood washing

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The advent of targeted therapy has increased treatment options for newly diagnosed patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)
.

Compared with chemotherapy alone, drugs that inhibit FLT3 kinase activity (alone or in combination with chemotherapy) significantly improve survival and remission rates in AML patients

Compared with chemotherapy alone in leukemia , drugs that inhibit FLT3 kinase activity (single or in combination with chemotherapy) significantly improve the survival rate and remission rate of AML patients.

A preliminary analysis by ADMIRAL showed that gilteritinib significantly prolonged overall survival compared with salvage chemotherapy (9.
3 months vs 5.
6 months; hazard ratio for death [HR] 0.
64, p<0.
001)
.

Gilteritinib significantly prolonged overall survival compared with salvage chemotherapy (9.
3 months vs 5.
6 months; hazard ratio for death [HR] 0.
64, p<0.
001)
.

Gilteritinib significantly prolonged overall survival compared with salvage chemotherapy (9.

However, the short follow-up time at the time of the primary analysis of the ADMIRAL trial limited the assessment of long-term outcomes
.

Therefore, investigators conducted extended follow-up of the ADMIRAL trial, and this article reports efficacy and safety results for an additional two years of follow-up from the initial analysis

Research Process

At the time of this analysis, with a median follow-up of 37.
1 months, 203 (247 total) and 97 (124 total) patients in the Gilteritinib group and salvage chemotherapy group had died, respectively; 16 patients in the Gilteritinib group were still receiving treatment
.

The median overall survival was 9.

Overall survival in both groups

The two-year cumulative relapse rate in the gilteritinib group was 75.
7%, with fewer relapses occurring after 18 months of follow-up
.

Overall, 49 of 247 patients in the gilteritinib group and 14 of 124 in the salvage chemotherapy group survived for two years or more

stem cell

side effect

The most common side effect is elevated liver enzymes
.

In conclusion , maintenance therapy with Gilteritinib maintained durable remission in patients with relapsed/refractory AML with a stable safety profile
.

The results of this study confirm that prolonged Gilteritinib treatment is safe and has better survival compared with S salvage chemotherapy

, Gilteritinib maintenance therapy can maintain relapsed/refractory AML patients achieve durable remission with stable safety , Gilteritinib maintenance therapy can maintain relapsed/refractory AML patients achieve durable remission with stable safety

Original source:

Alexander E.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.